Rare Disease Cures Accelerator - Data and Analytics Platform

RDCA-DAP is an FDA-funded initiative that provides a centralized and standardized infrastructure to support and accelerate rare disease characterization with the goal of accelerating therapy development across rare diseases. RDCA-DAP promotes the sharing of existing patient-level data and encourages the standardization of new data collection. By integrating data in a format suitable for analytics, RDCA-DAP accelerates the understanding of disease progression (including sources of variability to optimize the characterization of subpopulations), clinical outcome measures and biomarkers, and facilitates the development of mathematical models of disease and innovative clinical trial designs.RDCA-DAP是一项由美国食品药品监督管理局（Food and Drug Administration，FDA）资助的研究计划，旨在搭建集中化、标准化的基础设施以支持并加速罕见病特征解析，核心目标为推动全品类罕见病的治疗研发进程。该计划推动现有患者级数据的共享，并鼓励新型数据采集的标准化工作。通过采用适配分析需求的格式整合数据，RDCA-DAP可深化对疾病进展（包括明确变异来源以优化亚群特征解析）、临床结局指标与生物标志物的认知，并助力疾病数学模型构建与创新型临床试验设计的研发。

搜集汇总

背景与挑战

背景概述

RDCA-DAP是一个由FDA资助的中心化数据分析平台，旨在通过整合和标准化患者数据来加速罕见病的表征与治疗开发。它促进现有数据的共享和新数据收集的标准化，以支持对疾病进展、临床结果和生物标志物的理解，并推动疾病数学模型和创新临床试验设计的发展。该平台涵盖超过40种罕见病，为研究人员提供可访问的数据资源。